+9

GLP-1 Revolution

SPOT · 12 assetsmoderate risk1d

Holds: X:LLY-USD, X:AMGN-USD, X:TMO-USD + 9 more

Obesity is no longer a lifestyle problem — it's the largest addressable drug market of the decade. Eli Lilly posted $12.9B from GLP-1 drugs in a single quarter. Novo Nordisk's oral Wegovy hit 50,000 weekly prescriptions within three weeks of launch. Amgen's MariTide promises monthly or even quarterly dosing that could reshape patient compliance entirely. The injectable era opened the market. The oral era — now live with two pills on the market — is about to blow the doors off it. But the real story isn't just the drugs. Every injection needs a prefillable syringe (West Pharmaceutical), sterile fill-finish manufacturing (Thermo Fisher just built a 1.5B-unit-per-year production line), and subcutaneous delivery technology (Halozyme's ENHANZE platform is licensed by both Lilly and Amgen — they collect royalties regardless of who sells more). Behind the supply chain, the next generation is already forming: Viking Therapeutics showed best-in-class Phase 2 data and is the most talked-about acquisition target in biotech. Structure Therapeutics is building an oral small-molecule GLP-1 that doesn't need peptide manufacturing at all. Healthcare ETFs like XLV and XBI give you exposure to this theme buried inside hundreds of holdings — hospital operators, generic drugmakers, insurance companies, dental suppliers — that have nothing to do with the GLP-1 revolution. This strategy strips away the noise and concentrates on 12 high-conviction names across three layers: the drug makers writing blockbuster prescriptions, the manufacturers scaling to meet demand, and the challengers that could be acquired at a 50% premium overnight. The strategy isn't passive. When biotech enters a sustained downtrend, it automatically moves speculative positions to cash and preserves capital in the revenue-backed core. Each month it ranks every holding by momentum and rotates the weakest names out for the strongest opportunities in. Before earnings and FDA catalyst dates — events that can move biotech stocks 20-30% overnight — it trims profitable positions to lock in gains. A healthcare ETF just sits there and absorbs the drawdown. This strategy was built to manage the volatility that comes with owning the future of metabolic medicine.